Related Experiment Video
Updated: Dec 5, 2025
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
T-cell-engaging Therapy for Solid Tumors
Maria de Miguel1, Pablo Umana2, Ana Luiza Gomes de Morais1
1START Madrid-HM Centro Integral Oncológico Clara Campal (CIOCC) Early Phase Program, HM Sanchinarro University Hospital, Madrid, Spain.
Abstract:
T-cell engagers (TCE) are a rapidly evolving novel group of treatments that have in common the concurrent engagement of a T-cell surface molecule and a tumoral cell antigen. Bispecific antibodies and genetically engineered adoptive cell therapies, as chimeric antigen receptors or T-cell receptors, have similarities and differences among their mechanisms of action, toxicity profiles, and resistance pathways. Nevertheless, the success observed in the hematologic field has not been obtained with solid tumors yet, as they are biologically more complex and have few truly tumor-specific cell surface antigens that can be targeted with high avidity T cells. Different strategies are under study to improve their short-term perspective, such as new generations of more active TCEs, multi-target or combination of different treatments approaches, or to improve the manufacturing processes. A comprehensive review of TCEs as a grouped treatment class, their current status, and research directions in their application to solid tumors therapeutics are discussed here.
Insights
T-cell engagers (TCEs) show promise in cancer therapy by linking T-cells to tumor cells. Current research focuses on overcoming challenges in solid tumors to expand their therapeutic applications.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- T-cell engagers (TCEs) represent a novel therapeutic class concurrently engaging T-cells and tumor antigens.
- Existing TCEs include bispecific antibodies and adoptive cell therapies like CARs and TCRs, each with distinct mechanisms, toxicities, and resistance pathways.
Purpose of the Study:
- To provide a comprehensive review of TCEs as a treatment class.
- To discuss the current status and future research directions for TCEs in solid tumor therapeutics.
Main Methods:
- Review of existing literature on T-cell engagers.
- Analysis of similarities and differences between various TCE modalities.
- Examination of challenges and strategies for solid tumor application.
Main Results:
- TCEs have shown significant success in hematologic malignancies but face challenges in solid tumors due to biological complexity and lack of specific antigens.
- Ongoing strategies include developing next-generation TCEs, multi-targeting approaches, combination therapies, and improved manufacturing processes.
Conclusions:
- Significant advancements are needed to translate TCE success from blood cancers to solid tumors.
- Future research directions focus on enhancing TCE efficacy, specificity, and delivery for solid tumor treatment.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
02:17The Tumor Microenvironment